glp 1 news As GLP-1 Drugs Go Mainstream, This Expert Says Health is More than a Number on a Scale Medicare will now help pay

SGLT2 inhibitors appear more effective in mitigating glomerular hyperfiltration and lowering heart failure risk, whereas GLP-1 receptor agonists are particularly beneficial in reducing albuminuria and atherosclerotic cardiovascular events

Do not toss either in the household garbage or recycling

Full data is expected in mid-2026: which would put an FDA decision on the drug into late 2027 or 2028

Baseline characteristic and outcomes of CVOTs are listed in Table 2

In its statement, the FDA said it is also taking steps to combat misleading direct-to-consumer advertising and marketing following warning letters that were sent in the fall of 2025. The FDA specifically called out Hims in the announcement